Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Lymph node dissection may not be necessary for localized non-small cell lung cancers

Lymph node dissection, the current standard surgical treatment for localized non-small cell lung cancers, may be unnecessary in certain screen-detected early stage cases , according to a study published in the March issue of the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Sudden cessation of smoking may be symptom of lung cancer

Many longtime smokers quit spontaneously with little effort shortly before their lung cancer is diagnosed, leading some researchers to speculate that sudden cessation may be a symptom of lung cancer.

1 Mar 2011

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Although cancer in children is rare, more than 10,000 children in the United States are diagnosed with some form of the disease every year. If these children survive, studies have found that more than two-thirds develop at least one late-effect of treatment, which can include additional cancers, fertility and heart problems, limited limb function, and hearing loss.

1 Mar 2011

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

1 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P..

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

MEPs, OETC visit new TB vaccine trial site to express support for candidate development

Emergent BioSolutions Inc. announced that a joint delegation of Members of the European Parliament and representatives from the Oxford-Emergent Tuberculosis Consortium today visited the trial site where MVA85A, the world's most clinically advanced tuberculosis vaccine candidate in development, is being studied in a Phase IIb infant efficacy clinical trial.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Study: Radio-guided surgery effectively removes nodules in patients with lung cancer

Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques, Italian researchers report at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

28 Feb 2011

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

25 Feb 2011

Oncology News and Research

Further Reading

Lymph node dissection may not be necessary for localized non-small cell lung cancers

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

Sudden cessation of smoking may be symptom of lung cancer

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

Daiichi Sankyo enters merger agreement to acquire Plexxikon

TCD announces first patient treated in its TCD-717 Phase I trial

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Endo fourth quarter total revenues increase 31% to $511 million

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

p53 gene blocks EMT essential to cancer metastasis

MEPs, OETC visit new TB vaccine trial site to express support for candidate development

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Study: Radio-guided surgery effectively removes nodules in patients with lung cancer

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Avastin debate spills over until June FDA hearing

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

A best-practice guide for laboratory services in oncology trials eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News